Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(4):373-379; doi:10.1093/jnci/91.4.373
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Boyle, J. O.
Right arrow Articles by Dmitrovsky, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyle, J. O.
Right arrow Articles by Dmitrovsky, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 4, 373-379, February 17, 1999
© 1999 Oxford University Press


REPORTS

Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells

Jay O. Boyle, John Langenfeld, Fulvio Lonardo, David Sekula, Peter Reczek, Valerie Rusch, Marcia I. Dawson, Ethan Dmitrovsky

Affiliations of authors: J. O. Boyle (Laboratory of Molecular Medicine and Head and Neck Service), J. Langenfeld (Laboratory of Molecular Medicine and Thoracic Surgery Service), F. Lonardo (Laboratory of Molecular Medicine and Department of Pathology), D. Sekula (Laboratory of Molecular Medicine), V. Rusch (Laboratory of Molecular Medicine and Thoracic Surgery Service), E. Dmitrovsky (Laboratory of Molecular Medicine and Molecular Pharmacology and Therapeutics Program), Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY; P. Reczek, Bristol-Myers Squibb Pharmaceutical Research Institute, Buffalo, NY; M. I. Dawson, Retinoid Program, SRI International, Menlo Park, CA.

Correspondence to: Jay O. Boyle, M.D., Head and Neck Service,Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 (e-mail: jboyle{at}mskcc.org).

Present address:D. Sekula, Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH.

Present address: E. Dmitrovsky, Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH.

BACKGROUND: Retinoids (derivatives of vitamin A) are reported to reduce the occurrence of some second primary cancers, including aerodigestive tract tumors. In contrast, ß-carotene does not reduce the occurrence of primary aerodigestive tract cancers. Mechanisms explaining these effective retinoid and ineffective carotenoid chemoprevention results are poorly defined. Recently, the all-trans-retinoic acid (RA)-induced proteolysis of cyclin D1 that leads to the arrest of cells in G1 phase of the cell cycle was described in human bronchial epithelial cells and is a promising candidate for such a mechanism. In this study, we have investigated this proteolysis as a common signal used by carotenoids or receptor-selective and receptor-nonselective retinoids. METHODS: We treated cultured normal human bronchial epithelial cells, immortalized human bronchial epithelial cells (BEAS-2B), and transformed human bronchial epithelial cells (BEAS-2BNNK) with receptor-selective or receptor-nonselective retinoids or with carotenoids and studied the effects on cell proliferation by means of tritiated thymidine incorporation and on cyclin D1 expression by means of immunoblot analysis. We also examined whether calpain inhibitor I, an inhibitor of the 26S proteasome degradation pathway, affected the decline (i.e., proteolysis) of cyclin D1. RESULTS: Receptor-nonselective retinoids were superior to the carotenoids studied in mediating the decline in cyclin D1 expression and in suppressing the growth of bronchial epithelial cells. Retinoids that activated retinoic acid receptor ß or retinoid X receptor pathways preferentially led to a decrease in the amount of cyclin D1 protein and a corresponding decline in growth. The retinoid-mediated degradation of cyclin D1 was blocked by cotreatment with calpain inhibitor I. CONCLUSIONS: Retinoid-dependent cyclin D1 proteolysis is a common chemoprevention signal in normal and neoplastic human bronchial epithelial cells. In contrast, carotenoids did not affect cyclin D1 expression. Thus, the degradation of cyclin D1 is a candidate intermediate marker for effective retinoid-mediated cancer chemoprevention in the aerodigestive tract.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
Q. Feng, D. Sekula, Y. Guo, X. Liu, C. C. Black, F. Galimberti, S. J. Shah, L. F. Sempere, V. Memoli, J. B. Andersen, et al.
UBE1L causes lung cancer growth suppression by targeting cyclin D1
Mol. Cancer Ther., December 1, 2008; 7(12): 3780 - 3788.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. Nishikiori, M. Osanai, H. Chiba, T. Kojima, H. Ohguro, and N. Sawada
Inhibitory Effects of Retinoic Acid Receptor Alpha Stimulants on Murine Cataractogenesis through Suppression of Deregulated Calpains
Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2224 - 2229.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. H. Dragnev, W. J. Petty, S. J. Shah, L. D. Lewis, C. C. Black, V. Memoli, W. C. Nugent, T. Hermann, A. Negro-Vilar, J. R. Rigas, et al.
A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1794 - 1800.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
E. Dmitrovsky
D-Type Cyclins as Novel Targets for Chemoprevention
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 59 - 63.
[Full Text] [PDF]


Home page
JCOHome page
K. H. Dragnev, W. J. Petty, S. Shah, A. Biddle, N. B. Desai, V. Memoli, J. R. Rigas, and E. Dmitrovsky
Bexarotene and Erlotinib for Aerodigestive Tract Cancer
J. Clin. Oncol., December 1, 2005; 23(34): 8757 - 8764.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. J. Petty, N. Li, A. Biddle, R. Bounds, C. Nitkin, Y. Ma, K. H. Dragnev, S. J. Freemantle, and E. Dmitrovsky
A Novel Retinoic Acid Receptor {beta} Isoform and Retinoid Resistance in Lung Carcinogenesis
J Natl Cancer Inst, November 16, 2005; 97(22): 1645 - 1651.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Y. Park, A. Dillard, E. A. Williams, E. T. Wilder, M. R. Pepper, and M. A. Lane
Retinol Inhibits the Growth of All-Trans-Retinoic Acid-Sensitive and All-Trans-Retinoic Acid-Resistant Colon Cancer Cells through a Retinoic Acid Receptor-Independent Mechanism
Cancer Res., November 1, 2005; 65(21): 9923 - 9933.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Ma, Q. Feng, D. Sekula, J. A. Diehl, S. J. Freemantle, and E. Dmitrovsky
Retinoid Targeting of Different D-Type Cyclins through Distinct Chemopreventive Mechanisms
Cancer Res., July 15, 2005; 65(14): 6476 - 6483.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Guidoboni, P. Zancai, R. Cariati, S. Rizzo, J. Dal Col, A. Pavan, A. Gloghini, M. Spina, A. Cuneo, F. Pomponi, et al.
Retinoic Acid Inhibits the Proliferative Response Induced by CD40 Activation and Interleukin-4 in Mantle Cell Lymphoma
Cancer Res., January 15, 2005; 65(2): 587 - 595.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. J. Petty, K. H. Dragnev, V. A. Memoli, Y. Ma, N. B. Desai, A. Biddle, T. H. Davis, W. C. Nugent, N. Memoli, M. Hamilton, et al.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers
Clin. Cancer Res., November 15, 2004; 10(22): 7547 - 7554.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Pitha-Rowe, W. J. Petty, Q. Feng, P. H. Koza-Taylor, D. A. DiMattia, L. Pinder, K. H. Dragnev, N. Memoli, V. Memoli, T. Turi, et al.
Microarray Analyses Uncover UBE1L as a Candidate Target Gene for Lung Cancer Chemoprevention
Cancer Res., November 1, 2004; 64(21): 8109 - 8115.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. S. Kim, H. Lee, H. Kim, Y. M. Shim, J. Han, J. Park, and D.-H. Kim
Promoter Methylation of Retinoic Acid Receptor Beta 2 and the Development of Second Primary Lung Cancers in Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2004; 22(17): 3443 - 3450.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. S. Yang, K.-V. Chin, and J. D. Lambert
Cancer Chemoprevention by Targeting Proteasomal Degradation: Commentary re KA Dragnev et al, Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy. Clin Cancer Res, 2004;10:2570-7
Clin. Cancer Res., April 1, 2004; 10(7): 2220 - 2221.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. H. Dragnev, I. Pitha-Rowe, Y. Ma, W. J. Petty, D. Sekula, B. Murphy, M. Rendi, N. Suh, N. B. Desai, M. B. Sporn, et al.
Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy
Clin. Cancer Res., April 1, 2004; 10(7): 2570 - 2577.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Suzui, M. Shimizu, M. Masuda, J. T. E. Lim, N. Yoshimi, and I. B. Weinstein
Acyclic retinoid activates retinoic acid receptor {beta} and induces transcriptional activation of p21CIP1 in HepG2 human hepatoma cells
Mol. Cancer Ther., March 1, 2004; 3(3): 309 - 316.
[Abstract] [Full Text]


Home page
ChestHome page
K. H. Dragnev, D. Stover, and E. Dmitrovsky
Lung Cancer Prevention: The Guidelines
Chest, January 1, 2003; 123 (2009): 60S - 71S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Suzui, M. Masuda, J. T. E. Lim, C. Albanese, R. G. Pestell, and I. B. Weinstein
Growth Inhibition of Human Hepatoma Cells by Acyclic Retinoid Is Associated with Induction of p21CIP1 and Inhibition of Expression of Cyclin D1
Cancer Res., July 15, 2002; 62(14): 3997 - 4006.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Kitareewan, I. Pitha-Rowe, D. Sekula, C. H. Lowrey, M. J. Nemeth, T. R. Golub, S. J. Freemantle, and E. Dmitrovsky
UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia
PNAS, March 19, 2002; 99(6): 3806 - 3811.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. K. Joe, H. Liu, M. Suzui, M. E. Vural, D. Xiao, and I. B. Weinstein
Resveratrol Induces Growth Inhibition, S-phase Arrest, Apoptosis, and Changes in Biomarker Expression in Several Human Cancer Cell Lines
Clin. Cancer Res., March 1, 2002; 8(3): 893 - 903.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Witschi, I. Espiritu, M. Suffia, and K. E. Pinkerton
Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents
Carcinogenesis, February 1, 2002; 23(2): 289 - 294.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. D. Averbuch
Lung Cancer Prevention: Retinoids and the Epidermal Growth Factor Receptor--A Phoenix Rising?
Clin. Cancer Res., January 1, 2002; 8(1): 1 - 3.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Lonardo, K. H. Dragnev, S. J. Freemantle, Y. Ma, N. Memoli, D. Sekula, E. A. Knauth, J. S. Beebe, and E. Dmitrovsky
Evidence for the Epidermal Growth Factor Receptor As a Target for Lung Cancer Prevention
Clin. Cancer Res., January 1, 2002; 8(1): 54 - 60.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Dow, J. Hendley, A. Pirkmaier, E. A. Musgrove, and D. Germain
Retinoic Acid-mediated Growth Arrest Requires Ubiquitylation and Degradation of the F-box Protein Skp2
J. Biol. Chem., November 30, 2001; 276(49): 45945 - 45951.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. A. Papadimitrakopoulou, J. Izzo, L. Mao, J. Keck, D. Hamilton, D. M. Shin, A. El-Naggar, P. den Hollander, D. Liu, W. N. Hittelman, et al.
Cyclin D1 and p16 Alterations in Advanced Premalignant Lesions of the Upper Aerodigestive Tract: Role in Response to Chemoprevention and Cancer Development
Clin. Cancer Res., October 1, 2001; 7(10): 3127 - 3134.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. O. Boyle, F. Lonardo, J. H. Chang, D. Klimstra, V. Rusch, and E. Dmitrovsky
Multiple High-Grade Bronchial Dysplasia and Squamous Cell Carcinoma: Concordant and Discordant Mutations
Clin. Cancer Res., February 1, 2001; 7(2): 259 - 266.
[Abstract] [Full Text]


Home page
The OncologistHome page
K. H. Dragnev, J. R. Rigas, and E. Dmitrovsky
The Retinoids and Cancer Prevention Mechanisms
Oncologist, October 1, 2000; 5(5): 361 - 368.
[Abstract] [Full Text]


Home page
CarcinogenesisHome page
E. I. Salim, H. Wanibuchi, K. Morimura, S. Kim, Y. Yano, S. Yamamoto, and S. Fukushima
Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine
Carcinogenesis, February 1, 2000; 21(2): 195 - 203.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
H. Yu
Re: Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells
J Natl Cancer Inst, October 6, 1999; 91(19): 1685 - 1685.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.